Novogene(SH:688315) Sou Hu Cai Jing·2025-08-14 13:51Core Viewpoint - The company, Beijing Novogene Technology Co., Ltd., is experiencing a decline in stock price and has a lower price-to-earnings (PE) ratio compared to the industry average, indicating potential undervaluation in the context of its financial performance and market position [1][2]. Company Summary - The company's closing stock price on August 14 was 16.37 yuan, down 3.02%, with a rolling PE ratio of 33.50 times and a total market capitalization of 6.813 billion yuan [1]. - As of the 2025 semi-annual report, the company reported a revenue of 1.04 billion yuan, a year-on-year increase of 4.36%, and a net profit of 78.73 million yuan, a year-on-year increase of 1.03%, with a gross profit margin of 40.80% [1]. - The company has published or been cited in over 34,574 SCI articles with a cumulative impact factor of 227,372.12, and holds 82 invention patents and 547 software copyrights [1]. Industry Summary - The average PE ratio for the medical services industry is 49.00 times, with a median of 62.63 times, positioning Novogene at the 22nd rank within the industry [1][2]. - The company is among 12 institutions holding shares, with a total of 88.87 million shares held, valued at 1.255 billion yuan [1].